32 results about "Decidua" patented technology

The invention provides a method for preparing decidual mesenchymal stem cells, comprising using male full-term fetal placenta as raw material, aseptically treating the placenta; isolating decidual tissue; identifying decidual tissue and obtaining decidual mesenchymal stem cells from Identification of maternal tissue; culture of decidual mesenchymal stem cells; cryopreservation of decidual mesenchymal stem cells; recovery of decidual mesenchymal stem cells. The method of the present invention has the following technical features: collect the placenta where the fetus is male, and determine whether it comes from the mother through sex identification after obtaining the decidua tissue without contamination from the daughter tissue; prevent bacterial contamination, reduce the probability of contamination from the source of collection, and wash it multiple times The surface can effectively reduce the chance of contamination; the use of a single enzyme for digestion can simplify the process; the use of serum-free medium for culture reduces the use of animal-derived components, and the cell performance is stable, which can maintain the long-term culture of decidual mesenchymal stem cells in vitro, maintain cell shape, Proliferation ability, expression of MSC surface markers, differentiation ability, etc.

The invention belongs to the technical field of medicines, and in particular discloses application of fructose 1,6-diphosphate (FDP) in preparation of a fetus protection medicine for spontaneous abortion. In vitro and in vivo animal experiments show that the concentration of the FDP in peripheral blood and decidual tissues of patients with recurrent spontaneous abortion is decreased compared withnormal pregnancy. Compared with control pregnant mice, the model plasma and uterus FDP levels of pregnant mice with spontaneous abortion are reduced, the uterus macrophage M2 phenotype molecule expression of the pregnant mice with spontaneous abortion is decreased, the proportions of helper cells T(Th)2 and regulatory T cells are reduced, and the phenomena of poor endometrium decidualization and decreased embryonic trophoblast infiltration degree occur in an accompanied way. The results indicate that the supplement of the FDP can significantly improve the uterine immune tolerance pattern, decidualization and embryonic trophoblast infiltration in the pregnant mice with spontaneous abortion, and obviously reduces embryonic loss in the pregnant mice. Therefore, the FDP is expected to be an early-warning and diagnostic indicator for the patients with spontaneous abortion, and can be used for preparing the fetus protection medicine for the spontaneous abortion.

The invention relates to the technical field of biology, in particular to a tissue microarray of decidua and villi pairing, a preparation method and application thereof. The tissue microarray is prepared with the decidua and villus specimens of a normal pregnancy woman or a pathologic pregnancy patient arranged in sample application holes, so that pairing is formed between the decidua tissue and the villus tissue from the same specimen, and the functional presentation of the maternal-fetal interface of a physiological structure onto the tissue microarray is achieved. The tissue microarray has the advantages that high throughput is achieved, plenty of information is obtained in one time, and the efficiency is improved by hundreds of times; parallelization is achieved, the comparability is high, and the precision is high; the experimental error is small, and experimental conditions remain the same; convenience is brought to arrangement of various kinds of experimental control, and the research cost is greatly reduced. The tissue microarray can be used for etiology screening and molecular typing of pathologic pregnancy, screening and verifying of a novel marker, screening of individual treatment patients, judgment of a therapeutic effect and prognosis and the like, and the tissue microarray has important significance for the research of a normal pregnancy maintaining mechanism and pathologic pregnancy pathogenesis.

The invention discloses a method for preparing and freezing human placental amniotic membrane and decidua tissue, comprising: (1) washing the placenta; cutting off the decidual membrane along the edge of the placenta, and dividing the amniotic membrane into tissue pieces; The amniotic membrane on the fetal surface of the placenta is removed from the attached placental tissue; (2) Wash the amniotic membrane and decidua with normal saline or PBS buffer solution, fold or lay the amniotic membrane and decidua into a cryopreservation bag or cryopreservation tube , add 4°C cryopreservation solution, seal, transfer to a programmed cooling device, cool down to -80°C according to the set cooling program, and transfer to liquid nitrogen for cryopreservation. The cryopreservation method of the present invention is beneficial to improve the activity of cryopreserved tissues and cells, and the shape, function and structure after recovery are consistent with fresh tissues, and the overall survival rate of cells in the tissues is over 90%, and the preserved tissues can not only be used for separation Stem cells, epithelial cells and other fields can also be used in fields such as tissue engineering and transplantation.

The invention discloses a method for preparing and freezing human placental villi, comprising: (1) washing the placenta; cutting off the decidua along the edge of the placenta to remove the amnion; (2) removing the placenta from which the amnion has been removed The fetal facial chorion and large blood vessels are separated together, and the remaining placental tissue is the placental villi tissue. Cut the placental villi tissue into small pieces, and then cut them into thin slices; put the thin slices into cryopreservation bags or tubes, and proceed in three steps. Introduce the vitrification solution by using the method, transfer to the program cooling device, cool down to -80°C to -90°C, and transfer to liquid nitrogen for cryopreservation. The cryopreservation method of the present invention is beneficial to improve the activity of cryopreserved tissues and cells, and the shape, function, and structure after recovery are consistent with those of fresh tissues, and the overall survival rate of cells in the tissues is over 90%, and the preserved tissues can not only be used to separate stem cells , epithelial cells and other fields, and can also be used in fields such as tissue engineering and transplantation.

The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or adipose-derived stem cells show the effects of increasing leak point pressure and urethral sphincter contractility, and thus are useful as an agent for treating urinary incontinence.